Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBK002
- Development stage
- Unknown
- Lead developer
- Chengdu Shibeikang Biopharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SBK002 is a small molecule P2Y12 receptor antagonist developed by Chengdu Shibeikang Biopharmaceutical Technology Co., Ltd. for the prevention of atherothrombotic events. The drug works by selectively and reversibly binding to the P2Y12 receptor on the surface of platelets, thereby inhibiting adenosine diphosphate (ADP)-induced platelet activation and aggregation. This mechanism is intended to reduce the risk of cardiovascular complications such as myocardial infarction and stroke. SBK002 is currently undergoing Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers.
02
Targets
P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on SBK002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBK002.